Fly News Breaks for July 10, 2019
Jul 10, 2019 | 08:38 EDT
Credit Suisse analyst Uy Ear assumed coverage of Ironwood with a Neutral rating and $14 price target.
News For IRWD From the Last 2 Days
Sep 18, 2019 | 05:24 EDT
Ironwood Pharmaceuticals (IRWD) announced that it has amended its collaboration agreement with AstraZeneca (AZN) for the development and commercialization of LINZESS in China. LINZESS was approved by the National Medical Products Administration for adults with IBS-C in China in January 2019. LINZESS is expected to be launched in China in the second half of 2019. Under the terms of the amended agreement, AstraZeneca will obtain exclusive rights to develop, manufacture and commercialize linaclotide in China, including Hong Kong and Macau, and will be responsible for all expenses associated with these activities. In return, Ironwood will receive up to a total of $125 million, including non-contingent payments totaling $35M paid in three installments through 2024 and up to $90M in commercial milestone payments contingent on the achievement of certain net sales targets. Additionally, Ironwood will receive royalties beginning in the mid-single-digit percent and increasing up to 20% based on annual net sales of LINZESS in China. In connection with the amended agreement, Ironwood will no longer be jointly funding the development and commercialization of linaclotide or sharing in the net profit from sales in China.